HomeTestsSearchRankProfile
mediumMCQNEET 20222026Biology
1 mark

In gene therapy of Adenosine Deaminase (ADA) deficiency, the patient requires periodic infusion of genetically engineered lymphocytes because:

  1. A
    Retroviral vector is introduced into these lymphocytes
  2. B
    Gene isolated from marrow cells producing ADA is introduced into cells at embryonic stages
  3. C
    Lymphocytes from patient’s blood are grown in culture, outside the body
  4. D
    Genetically engineered lymphocytes are not immortal cells

Solution & Step-by-step Explanation

In the gene therapy for ADA deficiency, functional ADA cDNA is introduced into the patient's own lymphocytes. However, because lymphocytes have a finite lifespan (they are not immortal), the patient must undergo periodic infusions of these engineered cells to maintain a functional immune system.

Practice this question

Try it yourself before checking the explanation above.

In gene therapy of Adenosine Deaminase (ADA) deficiency, the patient requires periodic infusion of genetically engineered lymphocytes because:
A
Retroviral vector is introduced into these lymphocytes
B
Gene isolated from marrow cells producing ADA is introduced into cells at embryonic stages
C
Lymphocytes from patient’s blood are grown in culture, outside the body
D
Genetically engineered lymphocytes are not immortal cells

Share This Question

biotechnologygene therapy

Related Questions

easyMCQ

Which one of the following statements is true?

easyMCQ

Which of the following statements is not correct?

easyMCQ

Which one of the following statements is correct?

easyMCQ

The product formed by the reaction of an aldehyde with a primary amine is:

easyMCQ

Which part of the tobacco plant is infected by Meloidogyne incognita?

easyMCQ

The term ecosystem was coined by:

Ready for a Full Test?

Practice with timed mock tests and track your performance across Biology.

Browse TestsLeaderboard

Discussion